AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will participate with one oral presentation and four posters at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, California, from November 1-5. The company will showcase clinical and preclinical data across various programs, including its ongoing Phase I/II study investigating the safety and efficacy of autologous TAC-T cells targeting human epidermal growth factor receptor 2 (HER2) in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151) and its CLDN18.2, GUCY2C and allogeneic TAC T cell technologies.
TAC01-HER2 is an innovative cell-based therapy that involves the utilization of genetically modified T cells derived from the patient themselves. These cells express a T-cell Antigen Coupler (TAC) which is designed to specifically recognize HER2 in tumors. In addition to the TAC01-HER2 candidate, the company is investigating TAC-GUCY2C for the treatment of colorectal cancer and TAC01-CLDN18.2 for the treatment of pancreatic ductal adenocarcinoma and gastric cancer.
